Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis  

作　　者：Pengju Yan Ningning Li Ming Ma Zhaoli Liu Huicui Yang Jinnan Li Chunlei Wan Shuliu Gao Shuai Li Longtai Zheng John LWaddington Lin Xu Xuechu Zhen 

机构地区：[1]Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences,Soochow University,Suzhou 215123,China [2]CAS Key Laboratory of Animal Models and Human Disease Mechanisms,and KIz-sU Joint Laboratory of Animal Model and Drug Development,and Laboratory of Learning and Memory,Kunming Institute of Zoology,the Chinese Academy of Sciences,Kunming 650223,China [3]School of Pharmacy and Biomolecular Sciences,RCSI University of Medicine and Health Sciences,Dublin 2,Ireland

出　　处：《Signal Transduction and Targeted Therapy》2023年第10期4949-4963,共15页信号转导与靶向治疗（英文）

基　　金：This research was funded by the National Innovation of Science and Technology-2030(Program of Brain Science and Brain-lnspired Intelligence Technology)Grant(2021ZD0204004);the National Natural Science Foundation of China(81973334,81773702)。

摘　　要：Substance use disorder remains a major challenge,with an enduring need to identify and evaluate new,translational targets for effective treatment.Here,we report the upregulation of Hypoxia-inducible factor-1α(HIF-1α)expression by roxadustat(Rox),a drug developed for renal anemia that inhibits HIF prolyl hydroxylase to prevent degradation of HIF-1α,administered either systemically or locally into selected brain regions,suppressed morphine(Mor)-induced conditioned place preference(CPP).

关 键 词：DRUG MORPHINE ANEMIA 

分 类 号：R730.5[医药卫生—肿瘤]